Coalesce Corporation
Coalesce Corporation is a private life-sciences advisory firm that identifies, validates, and implements advanced technologies for pharmaceutical, biotech, diagnostics, chemical, and government organizations through a senior advisor network.
- Company typePrivate
- Founded1992
- HeadquartersMill Valley, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Coalesce Corporation does
Coalesce Corporation is a private life-sciences technology advisory firm founded in 1992 (per company history) and headquartered in Mill Valley, California, with 11–50 employees. The company identifies, authenticates, and implements advanced, game-changing technologies for pharmaceutical, biotech, medical devices, diagnostics, chemical, and advanced materials organizations, acting as a technology intermediary between emerging-technology providers and end-user adopters. Its portfolio spans drug discovery (confocal microscopy for living specimens, imaging flow cytometry, gene expression and micro-fluidics platforms, bead-based miRNA/RNA/protein determination), drug development (massively parallel polymorph testing, electronic laboratory notebook software), manufacturing (automated weighing and dosing, genotyping microbial identification), and clinical research (electrochemiluminescence, human genome portals, microarray platforms, miRNA reagent kits). The firm also builds patent portfolios for clients, with documented examples including a 27-patent family that contributed to Celera's $671M sale and an expanded miRNA kit IP that supported successful market penetration.
The company's business model is professional services: clients engage Coalesce on a bespoke basis to investigate barriers, verify community-validated solutions, specify optimum embodiments, and facilitate technology adoption. Pricing is not publicly disclosed and is presumed quote-based given the enterprise consulting nature. Revenue streams fall into three categories — Technology Implementation Services (matching providers with end users), Technology Investment Advisory (working with venture and fund management groups to validate investment targets), and Foundation Investment Evaluation (advising charitable foundations and sponsors on emerging technology grants). Go-to-market is exclusively direct enterprise engagement with no resellers, marketplaces, or self-serve channels; client segments include pharmaceutical and biotech organizations (primary), technology providers and startups, technology investors, governments, charitable foundations, regulatory agencies, and world health agencies. The firm's competitive position rests on its network of top-level decision makers and the founder Dr. Courtney Anderson's track record — including previous co-founding of Dionex Corporation (acquired by Thermo Fisher for $2.1 billion in 2011) and XA Systems (sold to Compuware for $55 million).
Coalesce Corporation firmographics
Firmographics- Name
- Coalesce Corporation
- Legal name
- Coalesce Corporation
- Website
- https://coalesce.com
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Coalesce Corporation is a private life-sciences advisory firm that identifies, validates, and implements advanced technologies for pharmaceutical, biotech, diagnostics, chemical, and government organizations through a senior advisor network.
- Ownership category
- akta.pro rank
Where Coalesce Corporation is headquartered
LocationHeadquarters
- HQ city
- Mill Valley
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Coalesce Corporation business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Technology Implementation Services: Coalesce works with pharmaceutical, biotech, medical devices and diagnostics organizations to identify, validate, and implement advanced technologies. The company charges for its services in connecting technology providers with organizations, facilitating meetings, helping validate technologies, and implementing solutions.
- Technology Investment Advisory: Working with Venture Investment, Catalyst and Fund Management groups, Coalesce discovers and validates new technology platforms, services, approaches and advanced solutions that warrant investment. Helps determine preferred embodiment of solutions and can find optimum executives for management.
- Foundation Investment Evaluation: Coalesce evaluates new emerging technology platforms, services and approaches, as well as prospective recipient capabilities, standards, mission and likelihood of success. Also sponsors, specifies, develops and commercializes emerging solutions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Coalesce Corporation product offering
Product offeringCore offering
Coalesce Corporation identifies, authenticates, and implements advanced game-changing technologies for pharmaceutical, biotech, medical devices, diagnostics, and chemical organizations. The company acts as an intermediary that uses its network of senior decision-makers and opinion-leaders to specify optimum embodiments of existing and emerging technologies, then introduces validated solutions to organizations that can benefit from them. Coalesce also develops patent portfolios for clients based on community-identified market needs.
Product overview
Coalesce Corporation offers a technology identification and validation service that acts as an intermediary between scientific organizations and technology providers. The company's core offering is its advisory service that identifies major barriers affecting pharmaceutical, biotech, and chemical organizations, then specifies and implements validated emerging technologies to overcome these challenges. The portfolio includes various technology platforms such as Electrochemiluminescence (ECL) for IVD testing, confocal microscope technology for living specimen imaging, automated weighing and dosing systems, genotyping microbial identification systems, massively parallel polymorph testing platforms, electronic laboratory notebooks (ELN), imaging flow cytometers, human genome portal gateways, microarray platforms, gene expression technologies, micro-fluidics technologies, miRNA reagent kits, and personalized disease management solutions. These technologies span the drug discovery, drug development, manufacturing, and clinical research/testing lifecycle stages.
Differentiator
Problem solved
Functional benefit
Products and services
- Technology Identification & Validation Services End-to-end advisory engagement in which Coalesce identifies, authenticates, and implements advanced game-changing technologies across pharmaceutical, biotech, medical devices, diagnostics, chemical, and advanced materials organizations. Includes community-validated methodology, market research, embodiment specification, and introduction of validated solutions to relevant buyers.
- Patent Portfolio Development Services Engagement in which Coalesce conducts market research, identifies specific applications needed in industry and academia, and helps clients build comprehensive patent portfolios addressing identified market needs. Examples include the Celera 27-patent portfolio and the Febit miRNA kit patent family expansion.
- Technology Investment Advisory Service for Venture Investment, Catalyst, and Fund Management groups in which Coalesce discovers and validates new technology platforms, services, approaches, and advanced solutions that warrant investment. Helps determine preferred embodiment of solutions and identifies optimum executives for portfolio company management.
- Foundation Investment Evaluation Services Service for charitable foundations in which Coalesce evaluates emerging technology platforms, services, and approaches, as well as prospective recipient capabilities, standards, mission, and likelihood of success. Includes sponsoring, specifying, developing, and commercializing emerging solutions for high-impact health areas.
Quantifiable outcome
- $50 Million USD in materials savings through massively parallel polymorph testing platform
- +7 more outcomes
Companies that use Coalesce Corporation
Customer profileNamed customers2 records
Segments7 records
Ideal customer profiles5 records
Coalesce Corporation technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Coalesce Corporation partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered major and minor.
- IGENmajorCoalesce worked with startup IGEN which had IP around Electrochemiluminescence technology promising higher sensitivities, no need for radioisotopes, extremely low detection limits, and dynamic ranges over six orders of magnitude. Coalesce facilitated meetings between IGEN and pharmaceutical/diagnostic companies, helping validate the technology.
- NoranmajorCoalesce gathered input from premier life science groups to develop specifications for a confocal microscope that could work for both living and fixed tissue. Noran devoted their engineering team to developing a workable solution that could see into living biological materials without perturbation.
- CeleramajorCoalesce worked with Celera (early 2000s) which had only initially focused on sequencing the human genome with no scientific applications. Coalesce conducted three phases of market research over about a year to help Celera build a new patent portfolio of 27 patents and develop applications. Company was eventually sold to Quest Diagnostics for ~$671 million.
- FebitmajorCoalesce worked with Febit, a startup with a new diagnostic platform - miRNA reagent kits that was too expensive at ~$21K and had limited IP. Coalesce validated market requirements and recommended keeping IP in-house and expanding the patent family to 4 more patents covering market demand.
- AmnismajorCoalesce worked with Amnis, a startup with new technology in search of applications for the intersecting communities of Flow Cytometry and Live Cell Imaging. Conducted research and interviews to uncover requirements needed to produce an ideal instrument, developing several new patent families including multi-parameter analysis and increased sensitivity.
- Dionex CorporationmajorCoalesce helped start, validate and invest in major new technologies including the first confocal microscope suitable for living specimens. Courtney Anderson was a principal founder of Dionex and helped push its growth to over $80 million in sales and a public offering. Dionex was later acquired by Thermo Fisher for $2.1 billion in 2011.
- XA SystemsminorCourtney Anderson co-founded XA Systems, a mainframe software utility company. As an investor and board member, helped direct growth to $35 million in sales. XA Systems was sold to Compuware Corporation for $55 million.
- Abbott LaboratoriesmajorProvided input through interviews on requirements for Amnis Imaging Flow Cytometer technology. Expressed needs for sub-cellular drug localization, multi-parameter analysis using fewer cells, sensitivity improvements, and quantification of multi-parameter multicolor fluorescence.
- CDC-Center for Infectious DiseasesmajorProvided input through interviews on requirements for Imaging Flow Cytometer. Expressed desire to quantify infected cells and process of infection, and noted that diagnostic assays will need FDA approval and should be tested against known assays.
- Roche DiagnosticsmajorRoche Diagnostics Division ultimately acquired the clinical rights to Electrochemiluminescence technology that Coalesce helped validate and facilitate implementation. The technology is now a highly sensitive IVD method constituting a large part of the $45+ billion global market.
- Quest DiagnosticsmajorAcquired Celera in May 2011 for around $671 million. Celera's new patent portfolio of 27 patents built with Coalesce's help was a key asset.
Scale indicators6 records
Recent moves6 records
Expansion highlights4 records
Coalesce Corporation competitors and assessment
Company assessmentDirect peers
- NineSigma: Open innovation services firm that connects large companies with external technology providers, running technology scouting and validation engagements. Directly comparable to Coalesce's technology identification and validation intermediary model.
- Yet2.com: Open innovation and technology transfer marketplace that helps companies source and validate external technologies, with a strong life sciences practice. Comparable to Coalesce as a technology intermediary and validation partner for life sciences and advanced technology clients.
- ClearView Healthcare Partners: Specialized life sciences strategy consulting firm serving pharma, biotech, and medtech clients on commercial strategy, technology assessment, and new product planning. Closely comparable to Coalesce in being a focused life sciences advisory firm serving enterprise R&D and commercial leaders.
- Health Advances: Specialized healthcare and life sciences strategy consulting firm advising biopharma, medtech, and diagnostics companies on technology evaluation, market assessment, and corporate development. Directly comparable to Coalesce in providing technology assessment and strategic advisory to pharma and biotech clients.
- Defined Health (now part of Campbell Alliance / Syneos): Specialized consulting firm focused on therapeutic innovation, business development, and corporate strategy for biopharma clients. Comparable to Coalesce in advising emerging biotech and pharma clients on technology strategy and product positioning.
Broad incumbents
- L.E.K. Consulting: Global strategy consulting firm with a dedicated Life Sciences practice that advises pharma, biotech, and medical device clients on technology evaluation, market entry, and growth strategy. Overlaps with Coalesce in serving enterprise pharma and biotech clients seeking technology and innovation advisory.
- ZS Associates: Large global consulting firm with a deep life sciences practice advising pharma and biotech on sales, marketing, and innovation strategy. Overlaps with Coalesce in serving enterprise pharma clients seeking technology and innovation advisory.
- Charles River Associates (CRA): Large global consulting firm with a Life Sciences practice that advises pharma and biotech on strategy, technology assessment, and transactions. Comparable to Coalesce in providing strategic advisory to life sciences clients, but with much broader service lines and a public-company footprint.
- McKinsey & Company (Pharma & Medical Products Practice): Global management consulting firm with a major Pharma & Medical Products practice advising on R&D strategy, technology assessment, and innovation. Comparable to Coalesce as a strategic advisor to pharma and biotech leadership on technology and innovation decisions.
Emerging players
- InnoCentive (now Wazoku): Open innovation and crowdsourced problem-solving platform that helps organizations source and validate external solutions, including in life sciences. Comparable to Coalesce's technology identification and validation model, though delivered through a digital platform rather than a high-touch advisory.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Coalesce Corporation social profiles
Digital presenceCoalesce Corporation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Coalesce Corporation leadership team
Management profileNumber of profiles
Profiles3 records
Coalesce Corporation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Coalesce Corporation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Coalesce Corporation
What does Coalesce Corporation do?
Coalesce Corporation identifies, authenticates, and implements advanced game-changing technologies for pharmaceutical, biotech, medical devices, diagnostics, and chemical organizations. The company acts as an intermediary that uses its network of senior decision-makers and opinion-leaders to specify optimum embodiments of existing and emerging technologies, then introduces validated solutions to organizations that can benefit from them. Coalesce also develops patent portfolios for clients based on community-identified market needs.
Is Coalesce Corporation a public or private company?
Coalesce Corporation is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Coalesce Corporation founded?
Coalesce Corporation was founded in 1992. It employs 11 to 50 people.
Where is Coalesce Corporation based?
Coalesce Corporation is headquartered in Mill Valley, United States, in the North America region.
How does Coalesce Corporation make money?
Three revenue lines are on record. Technology Implementation Services are the primary driver. The others are technology Investment Advisory and foundation Investment Evaluation.
Who are Coalesce Corporation's main competitors?
Direct peers on record are NineSigma, Yet2.com, ClearView Healthcare Partners, Health Advances and Defined Health (now part of Campbell Alliance / Syneos). Broad incumbents are L.E.K. Consulting, ZS Associates, Charles River Associates (CRA) and McKinsey & Company (Pharma & Medical Products Practice). InnoCentive (now Wazoku) is listed as an emerging player.
Does Coalesce Corporation have an API?
No public API is recorded for Coalesce Corporation.